Capsaicin prevents degeneration of dopamine neurons by inhibiting glial activation and oxidative stress in the MPTP model of Parkinson’s disease

被引:0
|
作者
Young C Chung
Jeong Y Baek
Sang R Kim
Hyuk W Ko
Eugene Bok
Won-Ho Shin
So-Yoon Won
Byung K Jin
机构
[1] College of Pharmacy,Department of Neuroscience
[2] Dongguk University,Department of Biochemistry and Signaling Disorder Research Center
[3] Graduate School,Department of Biochemistry and Molecular Biology
[4] Kyung Hee University,undefined
[5] School of Life Sciences,undefined
[6] BK21 plus KNU Creative BioResearch Group,undefined
[7] Kyungpook National University,undefined
[8] Brain Science and Engineering Institute,undefined
[9] Kyungpook National University,undefined
[10] Predictive model Research Center,undefined
[11] Korea Institute of Toxicology,undefined
[12] Korea Research Institute of Chemical Technology,undefined
[13] College of Medicine,undefined
[14] Chungbuk National University,undefined
[15] Neurodegeneration Control Research Center,undefined
[16] School of Medicine Kyung Hee University,undefined
来源
关键词
D O I
暂无
中图分类号
学科分类号
摘要
The effects of capsaicin (CAP), a transient receptor potential vanilloid subtype 1 (TRPV1) agonist, were determined on nigrostriatal dopamine (DA) neurons in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of Parkinson’s disease (PD). The results showed that TRPV1 activation by CAP rescued nigrostriatal DA neurons, enhanced striatal DA functions and improved behavioral recovery in MPTP-treated mice. CAP neuroprotection was associated with reduced expression of proinflammatory cytokines (tumor necrosis factor-α and interleukin-1β) and reactive oxygen species/reactive nitrogen species from activated microglia-derived NADPH oxidase, inducible nitric oxide synthase or reactive astrocyte-derived myeloidperoxidase. These beneficial effects of CAP were reversed by treatment with the TRPV1 antagonists capsazepine and iodo-resiniferatoxin, indicating TRPV1 involvement. This study demonstrates that TRPV1 activation by CAP protects nigrostriatal DA neurons via inhibition of glial activation-mediated oxidative stress and neuroinflammation in the MPTP mouse model of PD. These results suggest that CAP and its analogs may be beneficial therapeutic agents for the treatment of PD and other neurodegenerative disorders that are associated with neuroinflammation and glial activation-derived oxidative damage.
引用
收藏
页码:e298 / e298
相关论文
共 50 条
  • [21] Parkin and Differential Susceptibility of Nigrostriatal and Tuberoinfundibular Dopamine Neurons in an MPTP Model of Parkinson's Disease
    Behrouz, B.
    Lookingland, K.
    Goudreau, J.
    CELL TRANSPLANTATION, 2009, 18 (02) : 209 - 209
  • [22] CB2 receptor activation prevents glial-derived neurotoxic mediator production, BBB leakage and peripheral immune cell infiltration and rescues dopamine neurons in the MPTP model of Parkinson’s disease
    Young C Chung
    Won-Ho Shin
    Jeong Y Baek
    Eun J Cho
    Hyung H Baik
    Sang R Kim
    So-Yoon Won
    Byung K Jin
    Experimental & Molecular Medicine, 2016, 48 : e205 - e205
  • [23] CB2 receptor activation prevents glial-derived neurotoxic mediator production, BBB leakage and peripheral immune cell infiltration and rescues dopamine neurons in the MPTP model of Parkinson's disease
    Chung, Young C.
    Shin, Won-Ho
    Baek, Jeong Y.
    Cho, Eun J.
    Baik, Hyung H.
    Kim, Sang R.
    Won, So-Yoon
    Jin, Byung K.
    EXPERIMENTAL AND MOLECULAR MEDICINE, 2016, 48 : e205 - e205
  • [24] Loss of dopamine neurons correlates to behavioral impairment in the MPTP-primate model of Parkinson's disease
    Lupien, SB
    Bjugstad, KB
    Blanchard, BC
    Cornelius, SK
    Redmond, DE
    Elsworth, JD
    Roth, RH
    Sladek, JR
    EXPERIMENTAL NEUROLOGY, 2005, 193 (01) : 252 - 252
  • [25] EFFECTS OF DHF ON OXIDATIVE STRESS IN MPTP-INDUCED PARKINSON'S DISEASE MODEL MICE
    Zhao, Zonggang
    Wang, Shengnan
    Wang, Xinxin
    Sun, Lanlan
    ACTA MEDICA MEDITERRANEA, 2021, 37 (05): : 2675 - 2679
  • [26] Cholesterol contributes to dopamine-neuronal loss in MPTP mouse model of Parkinson's disease: Involvement of mitochondrial dysfunctions and oxidative stress
    Paul, Rajib
    Choudhury, Amarendranath
    Kumar, Sanjeev
    Giri, Anirudha
    Sandhir, Rajat
    Borah, Anupom
    PLOS ONE, 2017, 12 (02):
  • [27] The 5α-reductase inhibitor Dutasteride but not Finasteride protects dopamine neurons in the MPTP mouse model of Parkinson's disease
    Litim, Nadhir
    Bourque, Melanie
    Al Sweidi, Sara
    Morissette, Marc
    Di Paolo, Therese
    NEUROPHARMACOLOGY, 2015, 97 : 86 - 94
  • [28] CNB-001 a Novel Curcumin Derivative, Guards Dopamine Neurons in MPTP Model of Parkinson's Disease
    Jayaraj, Richard L.
    Elangovan, Namasivayam
    Manigandan, Krishnan
    Singh, Sonu
    Shukla, Shubha
    BIOMED RESEARCH INTERNATIONAL, 2014, 2014
  • [29] Minocycline prevents nigrostriatal dopaminergic neurodegeneration in the MPTP model of Parkinson's disease
    Du, YS
    Ma, ZZ
    Lin, SZ
    Dodel, RC
    Gao, F
    Bales, KR
    Triarhou, LC
    Chernet, E
    Perry, KW
    Nelson, DLG
    Luecke, S
    Phebus, LA
    Bymaster, FP
    Paul, SM
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2001, 98 (25) : 14669 - 14674
  • [30] Neuroprotective effects of Astilbin on MPTP-induced Parkinson's disease mice: Glial reaction, α-synuclein expression and oxidative stress
    Zhu, Ying-Li
    Sun, Meng-Fei
    Jia, Xue-Bing
    Cheng, Kun
    Xu, Yi-Da
    Zhou, Zhi-Lan
    Zhang, Pei-Hao
    Qiao, Chen-Meng
    Cui, Chun
    Chen, Xue
    Yang, Xu-Sheng
    Shen, Yan-Qin
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2019, 66 : 19 - 27